Market Overview

Jefferies Upgrades Karyopharm To Buy As STORM Data Likely To Predict Sunny Skies

Jefferies Upgrades Karyopharm To Buy As STORM Data Likely To Predict Sunny Skies

Jefferies has upgraded Karyopharm Therapeutics Inc (NASDAQ: KPTI) to Buy from Hold as it expects the upcoming STORM data to support Selinexor's potential in refractory multiple myeloma (MM), potentially driving near-term share upside.

The brokerage still sees potential for meaningful revenues, driven by a higher likelihood of Selinexor's ultimate success in MM. Despite the MM market being crowded, Jefferies believes there is still room for additional entrants — especially for those that provide novel mechanisms, like Selinexor — in later-line patients and in combinations.

Related Link: Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada

"We believe evolving efficacy/safety data, coupled with mgmt's expertise in the disease area and the continuing unmet need, increases the likelihood (our POS increases to 55 percent from 30 percent) Selinexor will ultimately reach the mkt and generate MM sales of >$500 million by 2025," analyst Brian Abrahams wrote in a note.

Near- And Long-Term Positives

Meanwhile, Selinexor is currently in 35 studies exploring multiple tumor types, increasing the potential to optimize indication, dosing and combination.

Based on preclinical results, Abrahams believes that data from next-gen XPO1 inhibitor '8602 later this year offer another means to exploit the potential of that agent to target the mechanism with fewer side effects with lower side effects. In addition, the PAK4/NAMPT inhibitor '9274 could potentially broaden the company's long-term opportunity.

"Though Selinexor's narrow therapeutic window remains the biggest limitation, recent studies (e.g., STOMP) at more optimized doses appear based on our analysis to suggest more acceptable AEs," Abrahams added.

Abrahams also raised the price target to $12 from $9, while the shares closed Monday's trading at $7.12.

At time of writing, Karyopharm shares were up 19.51 percent at $8.51 within the first half hour of Tuesday's regular trading session.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for KPTI

Nov 2020Morgan StanleyMaintainsOverweight
Nov 2020SVB LeerinkMaintainsOutperform
Aug 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for KPTI
View the Latest Analyst Ratings


Related Articles (KPTI)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Health Care Price Target Analyst Ratings Best of Benzinga

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at